China’s Next Wave of Innovation: 10 Breakthrough Drugs to Watch in H2 2026
The 10 breakthrough drugs to watch in H2 2026 in China span a wide range of therapeutic areas, including oncology, […]
The 10 breakthrough drugs to watch in H2 2026 in China span a wide range of therapeutic areas, including oncology, […]
HengYouDa Approved for PNH in China: Fumarate Licancopan Capsules (HengYouDa®) were approved by China’s National Medical Products Administration (NMPA) on
Tezepelumab Injection is a targeted biologic therapy that blocks TSLP to help control airway inflammation. On August 17, 2026, AstraZeneca
Over the past several decades, modern drug research and development has made remarkable progress across biomedicine, chemistry, and clinical research.
As the global pharmaceutical market continues to evolve, medicine procurement is gradually shifting from traditional offline channels toward more digital
Breast cancer is one of the most common malignant tumors among women worldwide. According to the World Health Organization (WHO),
On August 11, 2026, Enhertu® (generic name: trastuzumab deruxtecan, T-DXd) in combination with Pertuzumab was approved in China for the
Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer and is a highly heterogeneous
In recent years, Antibody-Drug Conjugates (ADCs) have continued to drive advances in precision oncology, gradually becoming one of the most
When it comes to maintaining good health, vitamins are among the most essential nutrients your body needs. From supporting the